drugset

drugset / Trial / NCT01478568

To Evaluate the Effect of Mirabegron (YM178) on Blood Levels of Desipramine When They Are Taken Together

NCT01478568 ↗

Phase 1 Completed 28 enrolled Astellas Pharma Inc

CrossoverOpen-label

Summary

The study aims to evaluate if blood levels of desipramine change whilst being dosed at the same time with daily mirabegron.

Timeline

Start: 2008-10
Primary completion: 2009-01
Completion: 2009-01

Publications

Background Krauwinkel W, Dickinson J, Schaddelee M, Meijer J, Tretter R, van de Wetering J, Strabach G, van Gelderen M. The effect of mirabegron, a potent and selective beta3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. Eur J Drug Metab Pharmacokinet. 2014 Mar;39(1):43-52. doi: 10.1007/s13318-013-0133-1. Epub 2013 Jun 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Desipramine	Small molecule	—	Oral
Subject	Mirabegron	Other / unclassified	—	Oral

Indications

No indication recorded.